This study will investigate the safety, tolerability and potential health benefits of the dietary supplement, Basis. There will be two doses of Basis compared to a placebo. One third of subjects will receive the low dose Basis, one third will receive the higher dose Basis and one third will receive placebo.

Inclusion Criteria:

• Males or females 60 to 80 (inclusive) years of age
• Body Mass Index (BMI) must be 18 to 35 kg/ m2 (±1 kg/m2)
• •Be able to make scheduled office visits 4 times during the study
• Willing to follow the instructions and complete multiple study questionnaires and assessments
• Agrees to avoid taking Vitamin B3 (Niacin, Nicotinic acid or niacinamide) supplements or multivitamins 14 days prior to randomization and for the duration of the study period
• Healthy otherwise as determined by laboratory results and medical history
• Has given voluntary, written, informed consent to participate in the study

Exclusion Criteria:

• History of any significant chronic disease or any clinically active illness within 3 months of study entry, including any history of renal or liver impairment, any endocrine, inflammatory, cardiovascular, gastro-intestinal, neurological, psychiatric, neoplastic or metabolic disease. Clinical significance of disease will be assessed by the Qualified Investigator and eligibility determined.
• Significant or untreated medical disorders including recent myocardial ischemia or infarction, unstable angina, uncontrolled hypertension, AIDS, malignancy, epilepsy, and recent cerebrovascular disease
• Subjects with or who have recently experienced a traumatic injury, infections or undergone surgery
• Subjects with history of pellagra or niacin deficiency
• Taking lipid lowering drugs
• Use of natural health products containing Nicotinamide riboside within 14 days prior to randomization and during the course of the study
• History of or current diagnosis of any cancer (except for successfully treated basal cell carcinoma) diagnosed less than 5 years prior to screening. Volunteers with cancer in full remission more than 5 years after diagnosis are acceptable
• Has participated in any clinical trial with an investigational medicinal product within the past three months prior to the first dose in the current study
• Unstable medical conditions
• Alcohol use >2 standard alcoholic drinks per day
• History of alcoholism or drug abuse within 1 year prior to screening
• History of significant allergies
• Allergy or sensitivity to any of the investigational product ingredients
• Use of medicinal marijuana
• Clinically significant abnormal laboratory results at screening
• Individuals who are cognitively impaired and/or who are unable to give informed consent
• Any other condition which in the Investigator's opinion may adversely affect the participant's ability to complete the study or its measures or which may pose significant risk to the participant